The latency-reversing agent HODHBt synergizes with IL-15 to enhance cytotoxic function of HIV-specific T cells

IL-15 is under clinical investigation toward the goal of curing HIV infection because of its abilities to reverse HIV latency and enhance immune effector function. However, increased potency through combination with other agents may be needed. 3-Hydroxy-1,2,3-benzotriazin-4(3H)-one (HODHBt) enhances...

Descripción completa

Detalles Bibliográficos
Autores principales: Copertino, Dennis C., Holmberg, Carissa S., Weiler, Jared, Ward, Adam R., Howard, J. Natalie, Levinger, Callie, Pang, Alina P.S., Corley, Michael J., Dündar, Friederike, Zumbo, Paul, Betel, Doron, Gandhi, Rajesh T., McMahon, Deborah K., Bosch, Ronald J., Linden, Noemi, Macatangay, Bernard J., Cyktor, Joshua C., Eron, Joseph J., Mellors, John W., Kovacs, Colin, Benko, Erika, Bosque, Alberto, Jones, R. Brad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561764/
https://www.ncbi.nlm.nih.gov/pubmed/37581929
http://dx.doi.org/10.1172/jci.insight.169028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561764/
https://www.ncbi.nlm.nih.gov/pubmed/37581929
http://dx.doi.org/10.1172/jci.insight.169028

Ejemplares similares